Mandy Cohen, director of the U.S. Centers for Disease Control and Prevention (CDC), pointed to mRNA as a preferred platform for the shot since vaccines can be developed and distributed quickly.

Years of earlier research — including Nobel-winning discoveries that were key to making the new technology work — gave a head start for so-called mRNA vaccines. Today, there’s also a more ...

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the ...

Instead they end in a conserved stem–loop that interacts with stem–loop binding protein (SLBP), a factor involved in several steps of histone mRNA metabolism: pre-mRNA processing, translation ...

Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor ...

Russia’s mRNA vaccine targets cancer using AI-powered personalisation Free distribution for Russian citizens begins in 2025 The vaccine trains the immune system to fight cancer effectively ...

The technology-driven Nasdaq-100 has delivered an impressive performance in 2024, posting a nearly 30% return year-to-date. This strong showing has been propelled by a few standout stocks, while ...

Russian news agency claims the country has developed an mRNA vaccine against cancer. It is set to be available free of charge to patients by 2025. Listen to Story The vaccine was developed in ...

By attaching short peptides to LNPs, scientists achieved targeted mRNA delivery to neurons and endothelial cells, avoiding invasive procedures. Peptides are smaller, more stable, and easier to use ...

TLR9 mRNA levels were normalized to β2-microglobulin mRNA levels and are presented as ... MDAM-MB-361 overexpressing pLVUT-TLR9 or pLVUT-TLR7 conditioned in doxycycline for 3-4 days then spun at 1000g ...

咪喹莫特（R837）是一种免疫佐剂，通过激活先天免疫系统中的TLR7受体，增强免疫细胞对肿瘤或病毒感染的免疫反应，常用于肿瘤免疫治疗和抗病毒治疗。介孔聚多巴胺（MPDA）纳米粒是一种具有良好生物相容性和高表面积的智能纳米材料，能够负载和控释药物 ...